Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor–induced colitis
Authors:
- Hajir IbraheimHIHajir Ibraheim
- Paolo Davide D’ARienzoPDPaolo Davide D’ARienzo
- Nathan James DeanNDNathan James Dean
- William DugglebyWDWilliam Duggleby
- Ashish SinghASAshish Singh
- Thubeena ManickavasagarTMThubeena Manickavasagar
- Foteini KalofonouFKFoteini Kalofonou
- Mohamed AboulelaMAMohamed Aboulela
- Sree VaderaSVSree Vadera
- Kirsty Ellen AndersonKAKirsty Ellen Anderson
- Michael CampbellMCMichael Campbell
- Jacob LewisJLJacob Lewis
Open Access
- 22 May 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 243, 116795
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Wellcome Trust
- Leona M. and Harry B. Helmsley Charitable Trust
- NIHR Imperial Biomedical Research Centre
- Imperial College London
- National Institute for Health and Care Research
- Imperial College Healthcare NHS Trust
This publication has 26 references indexed in Scilit:
- Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitisCancer Cell, 2024
- British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitisThe Lancet Gastroenterology & Hepatology, 2020
- Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwideInternational Journal of Colorectal Disease, 2020
- Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysisReviews in Medical Virology, 2019
- The detection of the cytomegalovirus DNA in the colonic mucosa of patients with ulcerative colitis is associated with increased long-term risk of proctocolectomy: results from an outpatient IBD clinicInternational Journal of Colorectal Disease, 2018
- Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisEuropean Journal of Cancer, 2017
- Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactionsCancer Treatment Reviews, 2017
- Cytomegalovirus, inflammatory bowel disease, and anti-TNFαInternational Journal of Colorectal Disease, 2017
- Cytomegalovirus Load in Inflamed Intestinal Tissue Is Predictive of Resistance to Immunosuppressive Therapy in Ulcerative ColitisAmerican Journal of Gastroenterology, 2011
- Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapyJournal of Clinical Virology, 2008